BryoLogyx Inc. is an emerging San Francisco Bay Area biopharmaceutical company focused on becoming a major clinical and commercial innovator in the eradication of HIV/AIDS and in cancer immunotherapy using synthetic Bryostatin-1 and potentially superior Bryologs. The Company has an option to obtain an exclusive worldwide license from Stanford University to intellectual property with respect to Bryostatin, created by the Wender Group at Stanford (see the description of Dr. Wender below).